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Some but not all neonates are affected by prenatal exposure to serotonin reuptake inhibitor antidepressants (SRI)
and maternal mood disturbances. Distinguishing the impact of these 2 exposures is challenging and raises critical
questions about whether pharmacological, genetic, or epigenetic factors can explain the spectrum of reported
outcomes. Using unbiased DNA methylation array measurements followed by a detailed candidate gene approach, we
examined whether prenatal SRI exposure was associated with neonatal DNA methylation changes and whether such
changes were associated with differences in birth outcomes. Prenatal SRI exposure was ﬁrst associated with increased
DNA methylation status primarily at CYP2E1(bNon-exposed D 0.06, bSRI-exposed D 0.30, FDR D 0); however, this ﬁnding
could not be distinguished from the potential impact of prenatal maternal depressed mood. Then, using
pyrosequencing of CYP2E1 regulatory regions in an expanded cohort, higher DNA methylation status—both the mean
across 16 CpG sites (P < 0.01) and at each speciﬁc CpG site (P < 0.05)—was associated with exposure to lower 3rd
trimester maternal depressed mood symptoms only in the SRI-exposed neonates, indicating a maternal mood x SRI
exposure interaction. In addition, higher DNA methylation levels at CpG2 (P D 0.04), CpG9 (P D 0.04) and CpG10 (P D
0.02), in the interrogated CYP2E1 region, were associated with increased birth weight independently of prenatal
maternal mood, SRI drug exposure, or gestational age at birth. Prenatal SRI antidepressant exposure and maternal
depressed mood were associated with altered neonatal CYP2E1 DNA methylation status, which, in turn, appeared to be
associated with birth weight.
Introduction
Prenatal exposure to maternal mood disturbances alter fetal
development and may set pathways that have long-term develop-
mental consequences.1 Prenatal exposure to maternal depression
is also associated with lower birth weight, short gestational
length, and neurobehavioral alterations during childhood.2–8 To
treat these prenatal mood disturbances, serotonin reuptake inhib-
itor (SRI) antidepressants can be prescribed, but such prenatal
SRI exposure was associated in some studies with preterm deliv-
ery, lower birth weight, changes in perceptual learning, congeni-
tal malformations, and neurobehavioral disturbances extending
from fetal periods to early childhood. 9–20 Therefore, in both
cases, adverse outcomes may occur, explaining why there are not
yet clear guidelines on how to treat depression during pregnancy.
Studies on epigenetic mechanisms are increasingly contribut-
ing to the improvement of our current understanding on the
association between prenatal exposure to maternal mood disor-
ders and/or antidepressants and the spectrum of neonatal out-
comes. Recent evidence now points to both exposures as factors
modulating the epigenetic regulation of gene expression.22 For
example, in mice, maternal stress increases transcription of the
DNA methyltransferases DNMT1 and DNMT3a in a tissue-spe-
cific manner, as well as the DNA methylation level of the placen-
tal enzyme 11b-hydroxysteroid dehydrogenase type 2 (11b-
HSD2) gene.23 Likewise, adult exposure to fluoxetine has been
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shown to increase global expression of histone deacetylase
HDAC5,28 HDAC2 in the caudate putamen,29 and miR-16 lev-
els in serotonergic raphe neurons in rodents.30 Other studies
report that chronic exposure to escitalopram leads to a reduction
in DNA methyltransferase (DNMT1 and 3a) and hypomethyla-
tion of the P11 promoter leading to an increase of P11 protein.31
Conversely, direct administration of inhibitors of histone deace-
tylase like sodium butyrate32 or MS-275,33 or of DNMT, such
as RG10834 or zebularine,35,36 or overexpression of histone
methyltransferases, such as G9A33,37 and SETDB1,38 exhibit
antidepressant-like effects in several behavioral assays.
Additionally, some studies have focused on the effect of prena-
tal maternal mood disorders on neonatal DNA methylation, sug-
gesting an association with NR3C1,24,39 SLC6A4,27,39 NFKB2,
FKBP5, and CRHR139; however, none of these genes have been
identified in studies taking an epigenome-wide approach.39,40
Similarly, prenatal SRI exposure has been found to be associated
with changes in neonatal DNA methylation in NR3C1,24,25,39
NFKB2, SLC6A4, FKBP5, and DNMT3a,39 but never by epige-
nome-wide approach.39,40 Instead, epigenome-wide studies, have
identified 1039 novel candidate genes associated with prenatal
maternal mood disorders and 2 (TNFRSF21 and CHRNA2)40
with prenatal SRI exposure. However, in all of these cases, the
biological significance of these findings was challenged by the
small mean DNA methylation difference between groups. There-
fore, additional studies may deepen our understanding on the
potential epigenetic link between prenatal mood, antidepressant
exposure, and DNA methylation.
In the present study, we investigated whether in utero SRI
exposure was associated with variations in the neonatal DNA
methylation status of > 27,000 CpG sites using umbilical cord
blood white blood cells (WBC). Guided by our microarray find-
ings, we undertook pyrosequencing of one putative candidate
gene, CYP2E1, using an expanded cohort to further determine
the impact of prenatal SRI exposure and to examine whether var-
iations in DNA methylation were influenced by antidepressant
exposure, antenatal maternal mood, or a combination of both.
Finally, we examined whether these outcomes were associated
with birth outcomes.
Results
The study cohort consisted of 44 women, including 19
depressed and SRI-treated and 25 not SRI-treated, prospectively
recruited during pregnancy (see Methods below). All mothers
were assessed at approximately 26 weeks and again at 36 weeks of
their pregnancy.We used a mean score of the 3rd trimester meas-
ures of maternal mood (Table 1A). Because maternal mood var-
ied both within and between groups, it was used as a continous
variable and treated as a covariable, where appropriate. With the
exception of higher depressed mood scores (mean prenatal) and
psychotropic medication use, maternal characteristics did not
vary significantly between groups (P > 0.05). All mothers took a
prenatal vitamin containing the typical prenatal folic acid dose
(0.8–1 mg).
Infant characteristics are presented in Table 1A. All infants
were full term, although gestational age at birth was significantly
reduced in SRI-exposed neonates (GANO_SRI D 40.3 wks,
GASRI D 37.0 wks, P < 0.01), as was head circumference (Head-
Circumf.NO_SRI D 35.3 cm, HeadCircumf.SRI D 32.5 cm, P D
0.01) and apgar at 1 min (Apgar1NO_SRI D 8.8, Apgar1SRI D
7.2, P < 0.01). SRI maternal and cord drug levels varied between
medications. However, fetal (cord)-maternal drug ratio remained
stable between drugs (mean: 0.73, sd: 0.33) (Table 1B), reflect-
ing the extent of transplacental transfer, fetal drug exposure, and
maternal and fetal capacity to metabolize the drug.
Microarray findings
To examine whether in utero exposure to SRIs alters neonatal
DNA methylation patterns at an epigenome level, we analyzed
the methylation profiles of > 27,000 CpG sites in genomic DNA
from cord blood in a subset of the whole cohort, which included
neonates with (n =12) and without (n D 11) prenatal SRI antide-
pressant exposure. After correcting for multiple testing, increased
methylation levels at 3 CpG sites were associated with prenatal
antidepressant exposure (FDR D 0): 1) CYP2E1 cg13315147
(bNon-exposed D 0.06, bSRI-exposed D 0.30) (Fig. 1); 2) EVA1
cg18399703 (bNon-exposed D 0.04, bSRI-exposed D 0.06) and; 3)
SLMAP cg11743795 (bNon-exposed D 0.02, bSRI-exposed D 0.03).
Among these candidates, we performed further analysis for the
CpG site with the highest methylation difference between non-
SRI and SRI-exposed neonates, CYP2E1, as it had the highest
likelihood of functional relevance. For this CpG site, a high
degree of correlation was found between maternal mood scores
and CYP2E1 DNA methylation values in the SRI-exposed group
(r2: ¡0.81, P < 0.01, n D 11), but not in the non-SRI group
(r2: 0.17, P D 0.58, n D 12), suggesting a mood x drug interac-
tion. To further test this hypothesis, we examined associations
between mean maternal 3rd trimester depression symptoms, in
utero SRI exposure status, and methylation status at the CYP2E1
CpG site in the whole cohort. This analysis revealed a main effect
for SRI exposure status (F(1,23) D 63.975, P < 0.01, ή2 D
0.771), as well as a significant interaction between maternal
mood and exposure status (F(1,23) D 29.229, P < 0.01, ή2 D
0.606), but not for maternal mood alone (F(1,23) D 3.93, P D
0.06, ή2 D 0.741) (DNA methylation differences 0.087 vs. 0.36,
non-SRI vs. exposed; Fig. 2; Table S1).
CYP2E1 has been associated twice previously with psycho-
genic stressors. In C57BL/6 mouse liver, chronic psychoemo-
tional stress reduces CYP2E1 protein levels 2-fold.42 Lam et al.
(2012)43 analyzed CYP2E1 DNA methylation in adult human
peripheral blood mononuclear cells (PBMC ) (n D 55), early
social economic status (SES), and depression values and revealed
a main effect for early SES (F(1,92) D 4.41, P D 0.039, ή2 D
0.048), but not for depression alone (F(1,92) D 0.545, P D
0.462, ή2 D 0.006) or for the interaction between early SES and
depression (F(1,92) D 1.57, P D 0.213, ή2 D 0.18) (Table S1).
The first study implicates that stress factors play a role in
CYP2E1 levels, and the latter suggests that early stress exposure
may induce long-term epigenetic changes on CYP2E1.
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Pyrosequencing findings
To confirm CYP2E1 DNA methylation values obtained by
microarray, we pyrosequenced the region including and sur-
rounding the relevant CYP2E1 CpG site (ch10:135,341,528,
NCBI36/hg19) interrogated on the microarray. We found that
DNA methylation values obtained by pyrosequencing and for
the CpG site on the microarray were correlated (r2 D 0.65, P <
0.01, n D 21). The pyrosequenced region contained 15 addi-
tional CpG loci in close proximity of the array CpG. All were
localized between C626 and C742 from the ATG of the
CYP2E1-001 ENST00000463117 transcript (Fig. 3), and their
DNA methylation values were correlated with each other (0.81
< r2< 0.98) (Fig. 4), suggesting use of the DNA methylation
mean as a reliable marker for this region. Moreover, DNA
methylation status (either by microarray or pyrosequencing) did
not vary with cord-maternal drug ratios (all P > 0.05).
These results encouraged us to further investigate the CYP2E1
DNA methylation difference observed between SRI and non-SRI
neonates in an expanded cohort that would enable us to examine
the possible concurrent influence of maternal mood disturbances.
Similar to the array findings, we found that increased 3rd trimes-
ter maternal mood was associated with lower CYP2E1 methyla-
tion only in the exposed (r2: ¡0.63, P < 0.01, n D 17) and not
for the non-SRI (r2: 0.11, P D 0.57, n D 25) infants across the
whole cohort (Fig. 5; Table S1).
When run on the whole pyrosequenced cohort, regression
analysis confirmed the main SRI exposure effect and the interac-
tion between maternal mood and SRI status on CYP2E1 mean
Table 1. A.Maternal and Fetal details
PYROSEQUENCED COHORT MICROARRAY COHORT
Non-SRI-exposed SRI-exposed Sig. Non-SRI-exposed SRI-exposed Sig.
Mean § SD (n) Mean § SD (n) Mean § SD (n) Mean § SD (n)
MATERNAL
DETAILS
Education (yrs) 17.46 § 2.98 (24) 16.65 § 4.57 (19) 0.93 16.59 § 2.81 (12) 17.55 § 3.83 (11) 0.5
HAM-Dy Score (Mean 26-36
wks Gest.)
7.06 § 5.10 (25) 10.51 § 5.73 (18) 0.02* 7.25 § 5.75 (12) 11.64 § 6.84 (11) 0.11
Smoking (yes/no) 0 (25) 0.05 § 0.23 (18) 0.33 0 (12) 0.09 § 0.30 (11) 0.34
Alcohol (no. of drinks for
entire pregnancy)
3.96 § 6.55 (25) 4.03 § 5.92 (18) 0.88 4.79 § 8.28 (12) 5.27 § 7.36 (11) 0.87
Maternal Age at birth (years) 34.3 § 5.2 (25) 31.3 § 7.9 (19) 0.28 34.0 § 5.9 (12) 31.9 § 4.9 (11) 0.36
Delivery type (vaginal/c/s) 20/5 (25) 16/3 (19) 11/1 (12) 11/0 (11)
Length Prenatal SRI
exposure (days)
0 (25) 272.1 § 9.6 (19) 0 (12) 270.8 § 10.2 (11)
Prenatal SRI Medications
(median mg/d)
Paroxetine — 25 § 7.1 (2) — 25 § 7.1 (2)
Fluoxetine — 46.7 § 23.1 (3) — 60 § 0 (2)
Sertraline — 175 § 35.4 (2) — 175 § 35.4 (2)
Citalopram — 40 § 0 (2) — 40 (1)
Venlafaxine — 159.5 § 53.9 (10) — 145.3 § 69.2 (4)
FETAL DETAILS Gender (m/f) (15/10) (25) (8/11) 0.25 6/6) (5/6) 0.84
Birth Gest. Age (wks) 40.3 § 1.1 (25) 37.0 § 8.8 (19) 5.10-4* 39.9 § 1.0 (12) 38.4 § 1.4 (11) 0.01*
Birth Weight (g) 3621 § 408 (25) 3245 § 768 (19) 0.22 3614 § 312 (12) 3352 §356 (11) 0.08
Head Circumference (cm) 35.34 § 0.99 (25) 32.53 § 7.76 (19) 0.01* 35.29 § 1.13 (12) 33.70 §1.28 (11) 5.10-3*
Apgar at 1 min. 8.76 § 0.52 (25) 7.22 § 2.15 (19) 1.10-3* 8.58 § 0.67 (12) 7.91 § 1.51 (11) 0.19
Apgar at 5 min. 9.04 § 0.35 (25) 8.55 § 1.98 (19) 0.57 9.0 § 0.43 (12) 9.0 § 0 (11) 1
B. SRI levels in the pyrosequensed cohort (ng/ml): Maternal (delivery), Neonatal (cord blood) and Fetal/Maternal ratio (delivery)
Maternal Drug Level
(Delivery)
Neonatal Drug Level
(Cord)
Fetal/Maternal
ratio Drug Level
(Delivery)
Mean § SD (n) Mean § SD (n) Mean § SD (n)
Fluoxetine 278.1 § 249.0 (3) 177.4 § 151 (3) 0.70 § 0.18 (3)
Norﬂuoxetine 228.3 § 154.3 (3) 153.2 § 101.0 (3) 0.73 § 0.26 (3)
Paroxetine 7.9 § 1.7 (2) 5.8 § 5.5 (2) 0.69 § 0.6 (2)
Sertraline 54.6 § 27.1 (2) 20.9 § 6.4 (2) 0.47 § 0.35 (2)
Citalopram 27.8 § 10.8 (2) 22.3 § 9.5 (2) 0.80 § 0.03 (2)
Venlafaxine 21.5 § 15.6 (6) 17.0 § 9.9 (7) 0.86 § 0.34 (6)
MEAN 0.74 § 0.33 (19)
www.tandfonline.com 3Epigenetics
CpG (P < 0.01 for both), as well as on each specific CpG site (P
< 0.05 for both) (Table S1). Moreover, we found a significant
maternal mood effect on CYP2E1 mean CpG methylation and
on 12 out of 16 pyrosequenced CpG sites.
Follow-up analysis to examine the direction of this interaction
was done by regression analysis on both non-SRI and exposed
groups with methylation status at CpG sites as the dependent
variable, and mean 3rd trimester maternal mood as predictor.
These were run separately for each group so there was no interac-
tion term in these analyses—that is, SRI exposure was not a fac-
tor. We found that increased prenatal 3rd trimester depressed
mood symptoms predicted lower levels of neonatal methyla-
tion—but only in the SRI-exposed group for the CpG mean
(b D ¡0.696, P D 0.001) (Fig. 6) and for all specific CpG sites
(Table S1). In the interaction between SRI exposure and mater-
nal mood, SRI exposure moderated the effect of mothers’ antena-
tal mood on DNA methylation, whereby maternal mood only
mattered to DNA methylation status with SRI exposure.
Birth outcomes
To examine whether neonatal CYP2E1 CpG methylation sta-
tus predicted indices of neonatal health, key birth outcome meas-
ures were examined in separate regression models with SRI
exposure status, mean maternal prenatal mood and an interaction
term between these key covariates. With the exception of birth
weight, no neonatal outcomes (gestational age, length, head
circumferance) were associated with methylation status at any of
the 16 CpG sites in CYP2E1. Decreased birth weight was pre-
dicted by decreased methylation status at CpG2 (b D 0.359; P
D 0.04), CpG9 (b D 0.352; P D 0.04), and CpG10 (b D
0.439; P D 0.02), regardless of SRI exposure and controlling for
gestational age at birth, mean antenatal depressed mood symp-
toms and the interaction between antenatal maternal mood and
SRI exposure status (Fig. 7, Table S1). Neonatal pyrosequencing
of CYP2E1 DNA methylation status did not vary significantly
with mode of delivery (cesarean section vs. vaginal delivery) (P >
0.05).
Discussion
CYP2E1 DNA methylation is associated with maternal
mood in SRI-exposed neonates
Using measures of both mean methylation status across 16
CpG sites and at specific CpG sites, this study reports an associa-
tion between higher DNA methylation status of CYP2E1 and
exposure to lower 3rd trimester maternal depressed mood symp-
toms in SRI-exposed neonates. Although it is not entirely clear
why CYP2E1 DNA methylation was associated only with mater-
nal mood in SRI exposed neonates, one possibility is that
CYP2E1 functions as a “buffer” against the adverse effects of SRI
exposure and thus acts to “protect” the developing fetus. Consis-
tent with this hypothesis, suppression of CYP2E1 expression in
mothers and neonates during late pregnancy has been hypothe-
sized to “protect” the fetus from oxidative stress in several
studies.44,45
Figure 1. Methylation level for CYP2E1 CpG in neonates exposed or not
to antidepressants. Range from 0 to 1. Differences between groups was
0.24. Colors represent mean HAMD maternal mood. Note exposed neo-
nates with high CYP2E1 DNA methylation level had mothers with low
HAMD maternal mood score, while exposed neonates with low DNA
methylation level had mothers with high HAMD scores.
Figure 2. Estimated CYP2E1 CpG methylation level using covariance
analysis for neonates exposed or not to antidepressants. DNA methyla-
tion levels for SRI- and non-exposed were 36% and 8.7%, respectively
(P < 0.05, controlling for mean HAMD maternal mood and interaction
between mean HAMD maternal mood and SRI exposure).
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CYP2E1 is a member of the hepatic cytochrome P450 oxidase
system found to be involved in the metabolism of numerous
xenobiotics, such as carcinogenic nitrosamines, benzene, low-
molecular-weight compounds and key enviromental exposures
including acetaminophen, volatile anesthetics, ethanol, and
tobacco, but not yet for antidepressants.46 The cytochrome P450
(CYP) 2D6 enzyme has been shown to be inhibited by some
SRIs, such as fluoxetine,47 suggesting the possibility that another
CYP family member like CYP2E1 might be indirectly inhibited
through SRI. Importantly, other key influences, such as CYP450
genetic variations, also influence SRI pharmacology and,
presumably, in utero drug exposure. While CYP450 genotyping
was beyond the scope of this study, fetal drug exposure (as
reflected by cord/maternal drug ratios) as a reflection of meta-
bolic capacity was not associated with DNA methylation status,
offering some, albeit indirect, evidence that our findings may
reflect an epigenetic mechanism that could potentially link SRI
exposure with birth outcomes.
The mechanism underlying regulation of neonatal CYP2E1
DNA methylation remains to be determined. A potential candi-
date for increased cord blood DNA methylation in SRI-exposed
neonates could involve the upregulation of DNA methyltransfer-
ase levels. Previous studies have shown an increase in placental
DNMT3a mRNA and DNMT1 in hypothalamus and cortex in
response to maternal stress.23,26 Furthermore, SRI antidepres-
sants have been associated with changes in gene expression associ-
ated with chromatin remodeling,48,49 histones,50 and increased
expression of methyl binding proteins MeCP2 and MBD1.29
Together, these studies suggest that either SRI and/or maternal
mood may have a direct or indirect effect on these molecules and
may participate in CYP2E1 DNA methylation levels.
Previous attempts using an epigenome-wide approach to identify
changes associated with prenatal SRI exposure have yielded
mixed results.39,40 One study failed to identify DNA methyla-
tion changes, and maternal mood was not accounted for in their
analytic models.39 This could be explained by a lack of data on
the severity of depression/anxiety (no HAM-D scores were
used), and, therefore, an inability to account for it in their ana-
lytic models. Moreover, the specific CYP2E1 site identified in
our current study was not included in the 450 K Illumina plat-
form used in that study. In another report,40 methylation differ-
ences at 2 (TNFRSF21and CHRNA2) CpG sites were associated
with prenatal SRI exposure. Importantly, the difference between
exposure groups was small (1–3%) raising questions about bio-
logical significance. Their cohort also included mothers with a
variety of mental health disorders (bipolar, schizophrenia) and
Figure 3. CYP2E1-001 (ENST00000463117) transcript structure. TSS, ATG, and CpG on the microarray were mapped to chromosome coordinates with
respect to the human genome build ch10:135,333,910, ch10:135,340,900 and ch10:135,341,528, respectively. Pyrosequenced CpGs were localized
betweenC626 and C742 from the ATG site.
Figure 4. Pearson correlation matrix describing methylation status of the
promoter region of CYP2E1 across 16 CpGs of all neonates. Scores range
from 0.8 to 1.
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exposure to additional psychotropic medications (e.g., hyp-
notics, benzodiazepines, antiemetics, bupropion, TCAs, atypical
antipsychotics), which may have introduced a spectrum of illness
severity and pharmacological factors beyond the characteristics
of our cohort. Future stud-
ies are needed to examine
epigenetic changes related
to illness severity and non-
serotonin specific psycho-
tropic medications.
CYP2E1 DNA
methylation level and birth
weight
Previous studies have
identified several epigeneti-
cally regulated genes associ-
ated with fetal growth
trajectories. In placenta,
high WNT2 promoter
methylation (WNT2PrMe),
high methylation of the glu-
cocorticoid receptor, and
low miR-16 and miR-21,
were found to be associated
with low birth weight.51–53
In cord blood, low methyla-
tion of the imprinted insu-
lin-like growth factor 2 (IGF2) gene was associated with high
birth weight.54
Our study links epigenetic variation to birth weight and fur-
ther links higher CYP2E1 DNA methylation for the CpG2, 9,
and 10 at birth and increased birth
weight that is independent of maternal
mood, SRI drug exposure, and gesta-
tional age at birth. These assocations
may suggest that high CYP2E1 methyla-
tion levels could reflect an as yet
unknown mechansim that could
“protect” the fetus from adverse SRI
effects, such as low birth weight. This is
supported by the observation that neo-
nates of mothers who received SRI treat-
ment but remained symptomatic had
lower DNA methylation levels and
lower birth weights, while neonates of
mothers who received SRI treatment but
did not remain symptomatic had higher
DNA methylation levels and higher
birth weights.
Indeed, maternal allelic variations in
CYP2E1 have been associated with
reduced birth weights and lengths, inde-
pendent of maternal smoking status.55
However, another study has not
reported an association between the 3
CYP2E1 genotypes tested and reduced
birth- weight,56 suggesting that other
important factors are involved in birth
weight outcomes. In fact, CYP2E1 may
Figure 5. Pearson correlation between maternal mood and neonatal methylation status of 16 CpGs within the pro-
moter region of CYP2E1. Scores were low for the non-exposed and high for SRI-exposed groups. The CpG2,
highlighted in red, was included on the microarray (ch10:135,341,528).
Figure 6. Methylation status of pyrosequenced CpG2 (ch10:135,341,528), maternal prenatal mood
(mean 3rd trimester), and SRI interaction. Increased prenatal maternal mood (mean HAMD) predicted
lower levels of neonatal DNA methylation in SRI-exposed, but not in the non-exposed group.
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have other developmental effects that
were not considered in this study. It is
a key cellular prooxidant and a source
of ROS,57 associated with increased
risk for cellular injury. Studies report
its implication in risks associated with
obesity,58 fasting,59 diabetes,60,61 liver
disease,62 Parkinson’s disease,63 and
non-syndromic oral cleft.64
Limitations
Previous studies have shown an
association between CYP2E1 DNA
methylation and CYP2E1 gene expres-
sion in different human tissues, such as
lung, liver, placenta, skin, and neu-
roma,65–68 but not in adult human
PBMC for this specific CYP2E1
CpG.43 Botto and colleagues, using a
3’ probe corresponding to positions
749–1,623 of the cDNA, showed that
hypomethylation of the 3’ end of the
coding region resulted in reduced
expression of the gene.69 It remains
unclear whether the modest differences
in CYP2E1 DNA methylation levels
between SRI- and non-exposed neo-
nates, and between low- and high-birth
weights, had an effect in terms of gene
expression, fetal physiological function,
or clinical relevance, especially in a
cohort in which birth weight remained
within the normal range (range: 2,679–4,805 grams).
A number of studies support a negative correlation between
DNA methylation and CYP2E1 expression within a single sam-
ple. For example, DNA methylation of specific 5’ residues in the
CYP2E1 gene has been associated with lack of CYP2E1 transcrip-
tion in fetal liver.67 Similarly, CYP2E1 transcription has been
associated with specific demethylation of CpG sites located in
the first-exon-first-intron region, suggesting that the location of
methylated CpG sites could play a role in the modulation of
CYP2E1 transcription rate. However, as was previously pub-
lished for a number of genes, CYP2E1 DNA methylation pat-
terns were not linked to expression levels when comparing
multiple samples.43
In addition, CYP2E1 is also within a known region of copy
number variation with common duplication alleles among differ-
ent populations.70 Duplicated CYP2E1 alleles have a probability
of 0.029 (n D 206) in caucasians and have been found in two 5’
promoter region repeat alleles, *1C (6 repeats) and *1D (8
repeats, frequency of 1% in caucasian) but never in CYP2E1*2,
*3, *4, *5, *6, or *7 variants.71 Although the biological implica-
tion of these findings remain unclear, they could potentially alter
the metabolism of drugs such as acetaminophen, isoniazid,
tamoxifen, and procarcinogens by modifying CYP2E1 enzyme
activity or by altering ethanol oxidation in the liver. To date,
only alleles of CYP2E1 (e.g., *1D, *5B, and *6) have been associ-
ated with alcoholism and cancer development in different ethno-
racial groups.72-76 Whether CNV has implications for fetal or
neonatal development following in utero SRI exposure remains
to be determined.
While we used fetal/maternal drug ratios as an index of fetal
drug exposure that might reflect maternal and neoantal drug met-
abolic capacity, this is a distal measure that was not able to distin-
guish exact contributing mechanisms. Beyond in utero SRI
exposure alone, factors such as maternal drug dose, differences in
SRI potency, maternal and fetal drug metabolism, and the role of
pregnancy itself may all influence the extent of fetal drug expo-
sure, thereby potentially contributing to inter-individual variabil-
ity of SRI responses in neonatal outcomes.1,21 Genetic variations
in CYP450 enzymes have been shown to alter SRI response in
adults,77 but limited evidence exists in neonates or infants.78 It is
conceivable that variability in outcomes following in utero SRI
exposure could be due to genetic variations in key regulatory
genes (e.g., 3A4, 2C19, 2D6).77 In the current study, we
included maternal and cord drug levels as well as fetal/maternal
ratios as index of the exent of fetal drug exposure. Given
Figure 7. Methylation status of pyrosequenced CpG2 (ch10:135,341,528), birth weight, and prenatal
SRI exposure. Increased birth weight predicted higher levels of neonatal DNA methylation status in
both groups.
www.tandfonline.com 7Epigenetics
differences in drug pharmacology and our small-sized cohort,
further study is needed to examine the impact of CYP450 genetic
variations on fetal drug exposure, DNA methylation status, and
developmental outcome.
The relationship between CYP2E1 DNA methylation and
CYP2E1 gene expression would then appear to be more complex
than a simple association of high DNA methylation levels with
low gene expression, in particular, when looking at its expression
across a large number of subjects. Notably, several factors are
involved in epigenetic variation, which may indirectly explain
why gene expression and DNA methylation correlation is not
always strong.79 Another important concern regards the further
interpretation of these DNA methylation differences in cell types
beyond venous cord blood (in this case, the brain).69 Notably,
early SRI exposure has been linked to later emerging neurological
symptoms, such as sensory map abnormalities,80 increased risk
for developmental delay,81 or ADHD.82 It will be important to
determine whether early CYP2E1 DNA methylation can contrib-
ute to these later phenotypes.
Conclusion
Prenatal exposure to maternal mood disturbances and SRI
antidepressant treatment are increasingly associated with altered
birth outcomes. Why some but not all infants are at-risk has led
to studies of epigenetic factors. Higher DNA methylation status
of CYP2E1, both across 16 CpG sites (mean) and at each CpG
site, was associated with exposure to lower 3rd trimester maternal
depressed mood symptoms, but only in SRI-exposed neonates.
Higher methylation levels at CpG2, CpG9, and CpG10 were
associated with increased birth weight, independently of maternal
mood, SRI drug exposure, and gestational age at birth. Instead,
neonates of mothers who received SRI treatment but remained
symptomatic (i.e., partial or non-responder) had the opposite
impact, namely lower DNA methylation levels and lower birth
weights. Molecular mechanisms underlying the links between
prenatal SRI/maternal mood exposure and neonatal epigenetic
changes, which might influence birth outcomes, remain to be
elucidated.
Methods
Subjects
With approval from the University of British Columbia
Research Ethics Board, Children’s and Women’s Health Center
of British Columbia Research Review Committee, and informed
parent consent, a cohort (n D 91) of mothers was recruited in
their early second trimester as part of a study of the impact of -
prenatal psychotropic medication exposure on neonatal health.
Of the original 91 mothers who completed a second trimester
data collection, 79 participated in a fetal speech perception study
at 36 weeks gestation.20 From these, a convenience sample of
cord blood obtained at delivery was chosen on the basis of SRI
exposure status and heart rate (HR) response during the fetal
language discrimination task.
An SRI-exposed group (n D 12) with greatest fetal HR
response was compared to a non-exposed group (n D 12) in
which the HR response was the weakest or non-existent on the
fetal language task. One sample from the SRI-exposed group was
excluded for a technical reason. These samples were then used to
study epigenetic marks associated with speech perception using a
genome-wide array approach to detect differences across >27,000
sites. However, as this approach did not detect whether any epi-
genetic differences were a result of SRI exposure, fetal capacity to
perceive speech, or maternal mood, DNA methylation differen-
ces were examined in a larger cohort using pyrosequencing.
The follow-up pyrosequencing sample included 21 out of 23
samples from the microarray cohort and 21 further samples from
the whole cohort. Two samples from the microarray cohort were
not included in the pyrosequenced cohort due to lack of DNA.
Nine neonates from the whole cohort were excluded either for
unavailable blood samples, or for experimental errors (n D 3). In
addition, we excluded subjects for either incomplete fetal percep-
tual HR records (n D 35) or fetal movement during the prenatal
perceptual task (n D 23).
Thirty-five neonates from the whole cohort were excluded for
either incomplete fetal perceptual HR records or fetal movement
during the prenatal perceptual task (n D 23), unavailable blood
samples (n D 9), or experimental errors (n D 3). Mothers were
included if they took no other serotonergic medications or psy-
chotropic medications during their pregnancy.
Demographic characteristics between infants in the array
cohort and the 21 additional infants of the pyrosequenced cohort
did not differ significantly with regard to maternal depressed
mood symptoms, maternal age at delivery, gestational age at
delivery, birth weight, length, or apgar scores, but differed signifi-
cantly for head circumference (SRI_array: 35.38, SRI_additional
samples: 35.19, P D 0.02) for the SRI-exposed groups.
Maternal mood
Prenatal maternal mood was assessed by averaged clinician-
rated measures (blinded to medication group status) derived
from assessements at the time of study enrollment (approxi-
mately 26 weeks) and at 36 weeks gestation. The Hamilton Rat-
ing Scale for Depression (HAM-D),83 a 21-item clinician
administered scale designed to assess the severity of depression
symptoms was used. Scores on this scale have a possible range of
0–63, with higher scores being associated with higher levels of
depression in the patient (Table 1).
Drug levels
Blood was drawn from SRI-treated mothers and venous cord
at delivery to assess medication plasma concentrations. Samples
were stored at ¡80C before being sent to CANTEST Ltd.,
where plasma concentrations of paroxetine, fluoxetine, norfluoxe-
tine (the major active metabolite of fluoxetine), sertraline, venla-
faxine, and citalopram were analyzed by high performance liquid
chromatography tandem mass spectrometry using atmospheric
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pressure electrospray ionization in positive mode. The limit of
quantification was 0.1 ng/L for all compounds analyzed.
DNA Extraction and Illumina Infinium
HumanMethylation27 array
Genomic DNA from neonate whole cord blood was
extracted using Qiagen DNA/RNA kit as per standard condi-
tions and bisulfite modified with the EZ DNA Methylation
Kit (Zymo Research) as per manufacturer’s instructions. This
step converted unmethylated cytosine into uracile but left
methylated cytosine (5-methylcytosine and 5-hydroxymethyl-
cytosine) or other potential methylated nucleotides, such as
methyladenine, unaffected. Then, bisulfite-converted DNA
was amplified, fragmented, and hybridized to Illumina Infin-
ium HumanMethylation27 BeadArray chips (Illumina, Inc.)
using Illumina supplied reagents and conditions. This array
enabled the simultaneous quantitative measurements of
27,578 CpG sites of 14,475 well-annotated human genes for
24 neonates whole cord blood.
DNA methylation array quality controls and data
normalization
Arrays were scanned on the Illumina iScan system and
imported into GenomeStudio for further analysis (2,010.2) using
BeadStudio (versions 3.1.3.0 Illumina, Inc.). Potential unreliable
CpGs or potential unreliable samples were removed, as well as
sexual chromosomes due to mixed sex population. A CpG was
considered unreliable if >10% of the samples had a detection P-
value > 0.1, and a sample was considered unreliable if >10% of
its CpGs had a detection P-value > 0.1. No CpG site or sample
was found to be unreliable. However, 1,092 CpG sites localized
on X or Y chromosomes were removed from the original dataset.
Then, we performed quantile normalization in R 2.11.0 using
the limma package.84
Statistical tests for DNA methylation differences
The non-parametric Wilcoxon test was used to identify meth-
ylation differences between SRI- and non-exposed newborns
using the built-in function of the SAMR package in R. Signifi-
cance Analysis of Microarrays (SAM) is a statistical technique
that has been developed to find significant gene expression differ-
ences in a set of microarray experiments and that corrects for
multiple testing.85 It uses repeated permutations of the data to
estimate false discovery rate. The cutoff for significance is deter-
mined by a tuning parameter delta, chosen by the user. The FDR
value is given by the q-value. Here, we used a 0.05 threshold.
Data reduction and statistical analyses
To examine relationships between antenatal SRI exposure and
neonatal DNA methylation status across 26,486 sites, we first
explored DNA methylation status using microarray data. Rela-
tionships between CYP2E1 neonatal DNA methylation, antena-
tal SRI exposure, and maternal mood were studied with the
univariate model using CYP2E1 DNA methylation level as
dependent variable, prenatal SRI exposure as independent vari-
able, and maternal mood as a covariate. Then, to confirm array
findings, SRI exposure-related methylation differences were
examined at specific CpG sites using pyrosequencing.
Relationships between CYP2E1 neonatal (cord) DNA
methylation, antenatal SRI exposure and maternal mood were
studied with linear regression models. As maternal mood
(delivery) measures were continuous and given that maternal
mood was highly correlated with SRI use, they were used as
predictors in all regression models. This also allowed us to
account for the wide range of depressive symptoms observed
among both SRI-treated and untreated groups across time, as
some mothers in our untreated group became depressed and
some crossed over to the SRI-treated group.
Relationships between newborn DNA methylation status and
birth outcomes were studied with linear regression models for
each neonatal outcome (i.e., gestational age, birth weight) using
prenatal maternal mood as a covariate. Given the exploratory
nature of these approaches, Bonferroni corrections were not
applied due to the heightened risk of associated Type II errors;
instead, effect sizes for the regressions (squared semi partial corre-
lations, ή2) were computed to allow examination of the magni-
tude of the predictive relationships.41
Validation and pyrosequencing
The BLAST program from NCBI was used to determine
whether candidate probe sequences mapped to a single unique loca-
tion in the genome or multiple sites. The repeat masker from
UCSC was used to determine whether candidate probes were
located in repetive elements. The UCSC site was also used to deter-
mine whether the candidate probe sequences and their surrounding
regions (100 upstream and downstream) contained any SNP.
Bisulfite pyrosequencing was used to validate the array study
for CYP2E1 and was performed in an expanded cohort. Pyrose-
quencing is a technique based on DNA sequencing in which
sequential incorporation of complementary nucleotides leads to
the production of a visible light that is proportional to the num-
ber of nucleotides incorporated. Preparation for pyrosequencing
was carried out using the PyroMark Q96 Vacuum Prep Work-
station (Qiagen) and the PyroMark Q96 ID pyrosequencer
(Qiagen) according to the manufacturer’s protocol.
In brief, for the samples that were not included on the array
in the expanded cohort or if additional bisulfite-converted
DNA used on the array was not available, genomic DNA
(500 ng) samples were bisulphite-treated and purified using
Zymogen EZ DNA Methylation Gold Kit (Zymo Research).
Both these samples and those that were run on the array for
which we still had bisulphite-converted DNA were amplified by
PCR. The PCR product was then bound to streptavidin-sephar-
ose high performance (GE healthcare), and the beads were agi-
tated for at least 5 min.
After a series of denaturing and wash steps resulting in the iso-
lation of single-stranded DNA, primer annealing was conducted
at 80C for 2 min. Pyrosequencing was then performed in a
PyroMark Q96 ID pyrosequencer (Qiagen) according to the
manufacturer’s instructions. The DNA methylation status of each
locus was analyzed individually using the Pyromark CpG 1.0.11
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software (Qiagen). Pearson correlation was then performed
between pyrosequencing and array DNA methylation values.
Pyrosequencing primers
CYP2E1 pyrosequencing primers were designed by EpigenDx
(http://www.epigendx.com/) and able to test up to 18 different
CpGs, but only 16 gave us pyrosequencing values. To assess
DNA methylation quality, we used samples with different global
methylated levels (0, 10, 25, 50, 75, 100%). The equation of the
curve obtained with the pyrosequenced values for all CpGs was y
D1.22x ¡3.45.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Acknowledgment
We are grateful to the mothers and their infants for participat-
ing in our study.
Funding
TFO is the R. Howard Webster Professor in Brain Imag-
ing and Early Child Development at the University of British
Columbia, supported by the Child and Family Research
Institute, NeuroDevNet NCE, and the Canadian Institutes
for Health Research [MOP-57837]. WMW received post
doctoral fellowship funding from CIHR and the Michael
Smith Foundation for Health Research. MSK is a Scholar of
the Djavad Mowafaghian Foundation also supported by funds
from NeuroDevNet NCE. This study was launched by a
Human Frontiers Science Program [RGP0018/2007] grant to
JFW, ME and TKH.
Supplemental Material
Supplemental data for this article can be accessed on the
publisher’s website.
References
1. Hanley GE, Oberlander TF. Neurodevelopmental out-
comes following prenatal exposure to serotonin reup-
take inhibitor antidepressants: a “social teratogen” or
moderator of developmental risk? Birth Defects Res A
Clin Mol Teratol 2012; 94:651-9; PMID:22733632
2. Talge NM, Neal C, Glover V. Antenatal maternal stress
and long-term effects on child neurodevelopment: how
and why? J Child Psychol Psychiat 2007; 48:245-61;
PMID:17355398; http://dx.doi.org/10.1111/j.1469-
7610.2006.01714.x
3. Steer RA, Scholl TO, Hediger ML, Fischer RL. Self-
reported depression and negative pregnancy outcomes.
J Clin Epidemiol 1992; 45:1093-9; PMID:1474405;
http://dx.doi.org/10.1016/0895-4356(92)90149-H
4. Pilowsky DJ, Wickramaratne P, Talati A, Tang M,
Hughes CW, Garber J, Malloy E, King C, Cerda G,
Sood AB, et al. Children of depressed mothers 1 year
after the initiation of maternal treatment: findings from
the STAR*D-Child Study. Am J Psychiat 2008;
165:1136-47; PMID:18558646; http://dx.doi.org/
10.1176/appi.ajp.2008.07081286
5. Grote NK, Bridge JA, Gavin AR, Melville JL, Iyengar
S, Katon WJ. A meta-analysis of depression during
pregnancy and the risk of preterm birth, low birth
weight, and intrauterine growth restriction. Arch Gen
Psychiat 2010; 67:1012-24; PMID:20921117; http://
dx.doi.org/10.1001/archgenpsychiatry.2010.111
6. Field T, Diego M, Hernandez-Reif M, Figueiredo B,
Schanberg S, Kuhn C, Deeds O, Contogeorgos J,
Ascencio A. Chronic prenatal depression and neonatal
outcome. The Int J Neurosci 2008; 118:95-103;
PMID:18041608; http://dx.doi.org/10.1080/
00207450601042144
7. Field T, Diego M, Hernandez-Reif M. Prenatal depres-
sion effects on the fetus and newborn: a review. Infant
Behav Dev 2006; 29:445-55; PMID:17138297; http://
dx.doi.org/10.1016/j.infbeh.2006.03.003
8. Diego MA, Field T, Hernandez-Reif M, Schanberg S,
Kuhn C, Gonzalez-Quintero VH. Prenatal depression
restricts fetal growth. Early Hum Dev 2009; 85:65-70;
PMID:18723301; http://dx.doi.org/10.1016/j.
earlhumdev.2008.07.002
9. Popa D, Lena C, Alexandre C, Adrien J. Lasting syn-
drome of depression produced by reduction in seroto-
nin uptake during postnatal development: evidence
from sleep, stress, and behavior. J Neurosci 2008;
28:3546-54; PMID:18385313; http://dx.doi.org/
10.1523/JNEUROSCI.4006-07.2008
10. Oberlander TF, Warburton W, Misri S, Riggs W,
Aghajanian J, Hertzman C. Major congenital
malformations following prenatal exposure to serotonin
reuptake inhibitors and benzodiazepines using popula-
tion-based health data. Birth Defects Res B, Dev
Reprod Ttoxicol 2008; 83:68-76; PMID:18293409;
http://dx.doi.org/10.1002/bdrb.20144
11. Noorlander CW, Ververs FF, Nikkels PG, van Echteld CJ,
VisserGH, SmidtMP.Modulation of serotonin transporter
function during fetal development causes dilated heart car-
diomyopathy and lifelong behavioral abnormalities. PLoS
One 2008; 3:e2782; PMID:18716672; http://dx.doi.org/
10.1371/journal.pone.0002782
12. Lisboa SF, Oliveira PE, Costa LC, Venancio EJ, Moreira
EG. Behavioral evaluation of male and female mice pups
exposed to fluoxetine during pregnancy and lactation. Phar-
macology 2007; 80:49-56; PMID:17519559; http://dx.
doi.org/10.1159/000103097
13. Grzeskowiak LE, Gilbert AL, Morrison JL. Neonatal
outcomes after late-gestation exposure to selective sero-
tonin reuptake inhibitors. J Clin Psychopharmacol
2012; 32:615-21; PMID:22926594; http://dx.doi.org/
10.1097/JCP.0b013e31826686bc
14. Grzeskowiak LE, Gilbert AL, Morrison JL. Investigat-
ing outcomes following the use of selective serotonin
reuptake inhibitors for treating depression in preg-
nancy: a focus on methodological issues. Drug saf
2011; 34:1027-48; PMID:21981432; http://dx.doi.
org/10.2165/11593130-000000000-00000
15. Gentile S. SSRIs in pregnancy and lactation: emphasis
on neurodevelopmental outcome. CNS Drugs 2005;
19:623-33; PMID:15984897; http://dx.doi.org/
10.2165/00023210-200519070-00004
16. Ellfolk M, Malm H. Risks associated with in utero and
lactation exposure to selective serotonin reuptake inhib-
itors (SSRIs). Reproductive toxicology (Elmsford, NY)
2010; 30:249-60; PMID:20447455
17. Berard A, Ramos E, Rey E, Blais L, St-Andre M, Orai-
chi D. First trimester exposure to paroxetine and risk of
cardiac malformations in infants: the importance of
dosage. Birth Def Res B Dev Reprod Toxicol 2007;
80:18-27; PMID:17187388; http://dx.doi.org/
10.1002/bdrb.20099
18. AnsorgeMS, ZhouM, Lira A,HenR,Gingrich JA. Early-
life blockade of the 5-HT transporter alters emotional
behavior in adult mice. Science 2004; 306:879-81;
PMID:15514160; http://dx.doi.org/10.1126/science.
1101678
19. Alwan S, Friedman JM. Safety of selective serotonin
reuptake inhibitors in pregnancy. CNS drugs 2009;
23:493-509; PMID:19480468; http://dx.doi.org/
10.2165/00023210-200923060-00004
20. Weikum WM, Oberlander TF, Hensch TK, Werker
JF. Prenatal exposure to antidepressants and depressed
maternal mood alter trajectory of infant speech percep-
tion. Proc Natl Acad Sci U S A 2012; 109 Suppl
2:17221-7; PMID:23045665; http://dx.doi.org/
10.1073/pnas.1121263109
21. Shea AK, Oberlander TF, Rurak D. Fetal serotonin
reuptake inhibitor antidepressant exposure: maternal
and fetal factors. CanJ Psychiatry 2012; 57:523-9;
PMID:23073029
22. Soubry A,Murphy S, Huang Z,Murtha A, Schildkraut J,
Jirtle R, Wang F, Kurtzberg J, Demark-Wahnefried W,
FormanM, et al. The effects of depression and use of anti-
depressive medicines during pregnancy on the methyla-
tion status of the IGF2 imprinted control regions in the
offspring. Clin Epigenet 2011; 3:2; PMID:22414206;
http://dx.doi.org/10.1186/1868-7083-3-2
23. Jensen Pena C, Monk C, Champagne FA. Epigenetic
effects of prenatal stress on 11beta-hydroxysteroid
dehydrogenase-2 in the placenta and fetal brain. PLoS
One 2012; 7:e39791; PMID:22761903; http://dx.doi.
org/10.1371/journal.pone.0039791
24. Oberlander TF, Weinberg J, Papsdorf M, Grunau R, Misri
S, Devlin AM. Prenatal exposure to maternal depression,
neonatal methylation of human glucocorticoid receptor
gene (NR3C1) and infant cortisol stress responses. Epige-
netics 2008; 3:97-106; PMID:18536531; http://dx.doi.
org/10.4161/epi.3.2.6034
25. Mulligan CJ, D’Errico NC, Stees J, Hughes DA. Meth-
ylation changes at NR3C1 in newborns associate with
maternal prenatal stress exposure and newborn birth
weight. Epigenetics 2012; 7:853-7; PMID:22810058;
http://dx.doi.org/10.4161/epi.21180
26. Mueller BR, Bale TL. Sex-specific programming of off-
spring emotionality after stress early in pregnancy. J
Neurosci 2008; 28:9055-65; PMID:18768700; http://
dx.doi.org/10.1523/JNEUROSCI.1424-08.2008
27. Devlin AM, Brain U, Austin J, Oberlander TF. Prena-
tal exposure to maternal depressed mood and the
MTHFR C677T variant affect SLC6A4 methylation in
infants at birth. PLoS One 2010; 5:e12201;
PMID:20808944
28. Benton CS, Miller BH, Skwerer S, Suzuki O, Schultz
LE, Cameron MD, Marron JS, Pletcher MT, Wiltshire
T. Evaluating genetic markers and neurobiochemical
analytes for fluoxetine response using a panel of mouse
inbred strains. Psychopharmacology 2012; 221:297-
315; PMID:22113448; http://dx.doi.org/10.1007/
s00213-011-2574-z
29. Cassel S, Carouge D, Gensburger C, Anglard P, Bur-
gun C, Dietrich JB, Aunis D, Zwiller J. Fluoxetine and
10 Volume 0 Issue 0Epigenetics
cocaine induce the epigenetic factors MeCP2 and
MBD1 in adult rat brain. Mol Pharmacol 2006;
70:487-92; PMID:16670375; http://dx.doi.org/
10.1124/mol.106.022301
30. Baudry A, Mouillet-Richard S, Schneider B, Launay
JM, Kellermann O. miR-16 targets the serotonin trans-
porter: a new facet for adaptive responses to antidepres-
sants. Science 2010; 329:1537-41; PMID:20847275;
http://dx.doi.org/10.1126/science.1193692
31. Melas PA, Rogdaki M, Lennartsson A, Bjork K, Qi H,
Witasp A, Werme M, Wegener G, Mathe AA, Sven-
ningsson P, et al. Antidepressant treatment is associated
with epigenetic alterations in the promoter of P11 in a
genetic model of depression. Int J neuropsychopharma-
col 2012; 15:669-79; PMID:21682946
32. Schroeder FA, Lin CL, Crusio WE, Akbarian S. Anti-
depressant-like effects of the histone deacetylase inhibi-
tor, sodium butyrate, in the mouse. Biol Psychiatry
2007; 62:55-64; PMID:16945350; http://dx.doi.org/
10.1016/j.biopsych.2006.06.036
33. Covington HE, 3rd, Maze I, LaPlant QC, Vialou VF,
Ohnishi YN, Berton O, Fass DM, Renthal W, Rush
AJ, 3rd, Wu EY, et al. Antidepressant actions of histone
deacetylase inhibitors. J Neurosci 2009; 29:11451-60;
PMID:19759294; http://dx.doi.org/10.1523/
JNEUROSCI.1758-09.2009
34. LaPlant Q, Vialou V, Covington HE, 3rd, Dumitriu
D, Feng J, Warren BL, Maze I, Dietz DM, Watts EL,
Iniguez SD, et al. Dnmt3a regulates emotional behav-
ior and spine plasticity in the nucleus accumbens. Nat
Neurosci 2010; 13:1137-43; PMID:20729844; http://
dx.doi.org/10.1038/nn.2619
35. Uchida S, Hara K, Kobayashi A, Otsuki K, Yamagata
H, Hobara T, Suzuki T, Miyata N, Watanabe Y. Epi-
genetic status of Gdnf in the ventral striatum deter-
mines susceptibility and adaptation to daily stressful
events. Neuron 2011; 69:359-72; PMID:21262472;
http://dx.doi.org/10.1016/j.neuron.2010.12.023
36. LaPlant Q, Vialou V, Covington HE, 3rd, Dumitriu
D, Feng J, Warren BL, Maze I, Dietz DM, Watts EL,
Iniguez SD, et al. Dnmt3a regulates emotional behav-
ior and spine plasticity in the nucleus accumbens. Nat
Neurosci 2010; 13:1137-43; PMID:20729844; http://
dx.doi.org/10.1038/nn.2619
37. Covington HE, 3rd, Maze I, Sun H, Bomze HM,
DeMaio KD, Wu EY, Dietz DM, Lobo MK, Ghose S,
Mouzon E, et al. A role for repressive histone methyla-
tion in cocaine-induced vulnerability to stress. Neuron
2011; 71:656-70; PMID:21867882; http://dx.doi.org/
10.1016/j.neuron.2011.06.007
38. Jiang Y, Jakovcevski M, Bharadwaj R, Connor C,
Schroeder FA, Lin CL, Straubhaar J, Martin G, Akbar-
ian S. Setdb1 histone methyltransferase regulates
mood-related behaviors and expression of the NMDA
receptor subunit NR2B. J Neurosci 2010; 30:7152-67;
PMID:20505083; http://dx.doi.org/10.1523/
JNEUROSCI.1314-10.2010
39. Non AL, Binder AM, Kubzansky LD, Michels KB.
Genome-wide DNA methylation in neonates exposed to
maternal depression, anxiety, or SSRI medication during
pregnancy. Epigenetics 2014; 9(7):964-72;
PMID:24751725; http://dx.doi.org/10.4161/epi.28853
40. Schroeder JW, Smith AK, Brennan PA, Conneely KN,
Kilaru V, Knight BT, Newport DJ, Cubells JF, Stowe
ZN. DNA methylation in neonates born to women
receiving psychiatric care. Epigenetics 2012; 7:409-14;
PMID:22419064; http://dx.doi.org/10.4161/epi.19551
41. Yau JL, Noble J, Chapman KE, Seckl JR. Differential
regulation of variant glucocorticoid receptor mRNAs in
the rat hippocampus by the antidepressant fluoxetine.
Brain Res Mol Brain Res 2004; 129:189-92;
PMID:15469896; http://dx.doi.org/10.1016/j.
molbrainres.2004.06.033
42. Maksymchuk O, Chashchyn M. The impact of psycho-
genic stressors on oxidative stress markers and patterns
of CYP2E1 expression in mice liver. Pathophysiology
2012; 19:215-9; PMID:22874632
43. Lam LL, Emberly E, Fraser HB, Neumann SM, Chen
E, Miller GE, Kobor MS. Factors underlying variable
DNA methylation in a human community cohort.
Proc Natl Acad Sci U S A 2012; 109 Suppl 2:17253-
60; PMID:23045638; http://dx.doi.org/10.1073/
pnas.1121249109
44. Koh KH, Xie H, Yu AM, Jeong H. Altered cytochrome
P450 expression in mice during pregnancy. Drug
Metab Dispos 2011; 39:165-9; PMID:20971892;
http://dx.doi.org/10.1124/dmd.110.035790
45. He XJ, Ejiri N, Nakayama H, Doi K. Effects of preg-
nancy on CYPs protein expression in rat liver. Exp Mol
Pathol 2005; 78:64-70; PMID:15596063; http://dx.
doi.org/10.1016/j.yexmp.2004.08.011
46. Gonzalez FJ. Role of cytochromes P450 in chemical
toxicity and oxidative stress: studies with CYP2E1.
Mutat Res 2005; 569:101-10; PMID:15603755;
http://dx.doi.org/10.1016/j.mrfmmm.2004.04.021
47. Otton SV, Wu D, Joffe RT, Cheung SW, Sellers EM.
Inhibition by fluoxetine of cytochrome P450 2D6 activ-
ity. Clin Pharmacol Ther 1993; 53:401-9;
PMID:8477556; http://dx.doi.org/10.1038/clpt.1993.43
48. Newton SS, Duman RS. Chromatin remodeling: a
novel mechanism of psychotropic drug action. Mol
Pharmacol 2006; 70:440-3; PMID:16728645; http://
dx.doi.org/10.1124/mol.106.027078
49. Hyman SE. Even chromatin gets the blues. Nat Neuro-
sci 2006; 9:465-6; PMID:16568101
50. Tsankova NM, Berton O, Renthal W, Kumar A, Neve
RL, Nestler EJ. Sustained hippocampal chromatin reg-
ulation in a mouse model of depression and antidepres-
sant action. Nat Neurosci 2006; 9:519-25;
PMID:16501568; http://dx.doi.org/10.1038/nn1659
51. Maccani MA, Padbury JF, Marsit CJ. miR-16 and
miR-21 expression in the placenta is associated with
fetal growth. PLoS One 2011; 6:e21210;
PMID:21698265
52. Filiberto AC, Maccani MA, Koestler D, Wilhelm-
Benartzi C, Avissar-Whiting M, Banister CE, Gagne LA,
Marsit CJ. Birth weight is associated with DNA promoter
methylation of the glucocorticoid receptor in human pla-
centa. Epigenetics 2011; 6:566-72; PMID:21521940;
http://dx.doi.org/10.4161/epi.6.5.15236
53. Ferreira JC, Choufani S, Grafodatskaya D, Butcher
DT, Zhao C, Chitayat D, Shuman C, Kingdom J,
Keating S, Weksberg R. WNT2 promoter methylation
in human placenta is associated with low birth weight
percentile in the neonate. Epigenetics 2011; 6:440-9;
PMID:21474991; http://dx.doi.org/10.4161/
epi.6.4.14554
54. Hoyo C, Fortner K, Murtha AP, Schildkraut JM,
Soubry A, Demark-Wahnefried W, Jirtle RL, Kurtz-
berg J, Forman MR, Overcash F, et al. Association of
cord blood methylation fractions at imprinted insulin-
like growth factor 2 (IGF2), plasma IGF2, and birth
weight. Cancer Causes Control 2012; 23:635-45;
PMID:22392079; http://dx.doi.org/10.1007/s10552-
012-9932-y
55. Sasaki S, Sata F, Katoh S, Saijo Y, Nakajima S, Wash-
ino N, Konishi K, Ban S, Ishizuka M, Kishi R. Adverse
birth outcomes associated with maternal smoking and
polymorphisms in the N-Nitrosamine-metabolizing
enzyme genes NQO1 and CYP2E1. Am J Epidemiol
2008; 167:719-26; PMID:18218609; http://dx.doi.
org/10.1093/aje/kwm360
56. Chen D, Hu Y, Yang F, Li Z, Wu B, Fang Z, Li J,
Wang L. Cytochrome P450 gene polymorphisms and
risk of low birth weight. Genet Epidemiol 2005;
28:368-75; PMID:15712341; http://dx.doi.org/
10.1002/gepi.20067
57. Cederbaum AI, Lu Y, Wu D. Role of oxidative stress in
alcohol-induced liver injury. Arch Toxicol 2009;
83:519-48; PMID:19448996; http://dx.doi.org/
10.1007/s00204-009-0432-0
58. Raucy JL, Lasker JM, Kraner JC, Salazar DE, Lieber
CS, Corcoran GB. Induction of cytochrome P450IIE1
in the obese overfed rat. Mol Pharmacol 1991; 39:275-
80; PMID:2005876
59. O’Shea D, Davis SN, Kim RB, Wilkinson GR. Effect of
fasting and obesity in humans on the 6-hydroxylation of
chlorzoxazone: a putative probe of CYP2E1 activity. Clin
Pharmacol Therapeut 1994; 56:359-67; PMID:7955797;
http://dx.doi.org/10.1038/clpt.1994.150
60. Wang Z, Hall SD, Maya JF, Li L, Asghar A, Gorski JC.
Diabetes mellitus increases the in vivo activity of cyto-
chrome P450 2E1 in humans. Br J Clin Pharmacol
2003; 55:77-85; PMID:12534643; http://dx.doi.org/
10.1046/j.1365-2125.2003.01731.x
61. Dong ZG, Hong JY, Ma QA, Li DC, Bullock J, Gon-
zalez FJ, Park SS, Gelboin HV, Yang CS. Mechanism
of induction of cytochrome P-450ac (P-450j) in chemi-
cally induced and spontaneously diabetic rats. Arch
Biochem Biophys 1988; 263:29-35; PMID:3285794;
http://dx.doi.org/10.1016/0003-9861(88)90610-8
62. Butura A, Nilsson K, Morgan K, Morgan TR, French
SW, Johansson I, Schuppe-Koistinen I, Ingelman-
Sundberg M. The impact of CYP2E1 on the develop-
ment of alcoholic liver disease as studied in a transgenic
mouse model. J Hepatol 2009; 50:572-83;
PMID:19157621; http://dx.doi.org/10.1016/j.jhep.
2008.10.020
63. Kaut O, Schmitt I, Wullner U. Genome-scale methyla-
tion analysis of Parkinson’s disease patients’ brains
reveals DNA hypomethylation and increased mRNA
expression of cytochrome P450 2E1. Neurogenetics
2012; 13:87-91; PMID:22238121; http://dx.doi.org/
10.1007/s10048-011-0308-3
64. Chevrier C, Perret C, Bahuau M, Nelva A, Herman C,
Francannet C, Robert-Gnansia E, Cordier S. Fetal and
maternal CYP2E1 genotypes and the risk of nonsyn-
dromic oral clefts. Am J Med Genet A 2007;
143A:1382-5; PMID:17506098; http://dx.doi.org/
10.1002/ajmg.a.31779
65. Botto F, Seree E, el Khyari S, de Sousa G, Massacrier A,
Placidi M, Cau P, Pellet W, Rahmani R, Barra Y. Tis-
sue-specific expression and methylation of the human
CYP2E1 gene. Biochem Pharmacol 1994; 48:1095-
103; PMID:7945402; http://dx.doi.org/10.1016/
0006-2952(94)90145-7
66. Botto F, Seree E, el Khyari S, Cau P, Henric A, De
Meo M, Bergeron P, Barra Y. Hypomethylation and
hypoexpression of human CYP2E1 gene in lung
tumors. Biochem Biophys Res Commun 1994;
205:1086-92; PMID:7802636; http://dx.doi.org/
10.1006/bbrc.1994.2777
67. Jones SM, Boobis AR, Moore GE, Stanier PM. Expres-
sion of CYP2E1 during human fetal development:
methylation of the CYP2E1 gene in human fetal and
adult liver samples. Biochem Pharmacol 1992;
43:1876-9; PMID:1575782; http://dx.doi.org/
10.1016/0006-2952(92)90726-Y
68. Vieira I, Sonnier M, Cresteil T. Developmental expres-
sion of CYP2E1 in the human liver. Hypermethylation
control of gene expression during the neonatal period.
European journal of biochemistry / FEBS 1996;
238:476-83; PMID:8681961
69. Botto F, Seree E, el Khyari S, Cau P, Henric A, De
Meo M, Bergeron P, Barra Y. Hypomethylation and
hypoexpression of human CYP2E1 gene in lung
tumors. Biochem Biophys Res Commun 1994;
205:1086-92; PMID:7802636; http://dx.doi.org/
10.1006/bbrc.1994.2777
70. Martis S, Mei H, Vijzelaar R, Edelmann L, Desnick RJ,
Scott SA. Multi-ethnic cytochrome-P450 copy number
profiling: novel pharmacogenetic alleles and mecha-
nism of copy number variation formation. Pharmaco-
genomics J 2013; 13:558-66; PMID:23164804; http://
dx.doi.org/10.1038/tpj.2012.48
71. Hu Y, Hakkola J, Oscarson M, Ingelman-Sundberg M.
Structural and functional characterization of the 5’-
flanking region of the rat and human cytochrome P450
2E1 genes: identification of a polymorphic repeat in
the human gene. Biochem Biophys Res Commun
1999; 263:286-93; PMID:10491286; http://dx.doi.
org/10.1006/bbrc.1999.1362
www.tandfonline.com 11Epigenetics
72. Das P, Shaik AP, Bammidi VK. Meta-analysis study of
glutathione-S-transferases (GSTM1, GSTP1, and
GSTT1) gene polymorphisms and risk of acute mye-
loid leukemia. Leuk Lymphoma 2009; 50:1345-51;
PMID:19811334; http://dx.doi.org/10.1080/
10428190903003236
73. Cho HJ, Eom HS, Kim HJ, Kim IS, Lee GW, Kong
SY. Glutathione-S-transferase genotypes influence the
risk of chemotherapy-related toxicities and prognosis in
Korean patients with diffuse large B-cell lymphoma.
Cancer Genet Cytogenet 2010; 198:40-6;
PMID:20303013; http://dx.doi.org/10.1016/j.
cancergencyto.2009.12.004
74. Farlow M, Gracon SI, Hershey LA, Lewis KW, Sadow-
sky CH, Dolan-Ureno J. A controlled trial of tacrine in
Alzheimer’s disease. The Tacrine Study Group. JAMA
1992; 268:2523-9; PMID:1404819; http://dx.doi.org/
10.1001/jama.1992.03490180055026
75. Kawas CH. Clinical practice. Early Alzheimer’s disease.
N Eng J Med 2003; 349:1056-63; PMID:12968090;
http://dx.doi.org/10.1056/NEJMcp022295
76. Patocka J, Jun D, Kuca K. Possible role of hydroxylated
metabolites of tacrine in drug toxicity and therapy of
Alzheimer’s disease. Curr Drug Metabol 2008; 9:332-5;
PMID:18473751; http://dx.doi.org/10.2174/
138920008784220619
77. Caudle KE, Klein TE, Hoffman JM, Muller DJ,
Whirl-Carrillo M, Gong L, McDonagh EM, Sangkuhl
K, Thorn CF, Schwab M, et al. Incorporation of phar-
macogenomics into routine clinical practice: the Clini-
cal Pharmacogenetics Implementation Consortium
(CPIC) guideline development process. Curr Drug
Metabol 2014; 15:209-17; PMID:24479687; http://
dx.doi.org/10.2174/1389200215666140130124910
78. Laine K, Kytola J, Bertilsson L. Severe adverse effects in
a newborn with two defective CYP2D6 alleles after
exposure to paroxetine during late pregnancy. Ther
Drug Monit 2004; 26:685-7; PMID:15570195; http://
dx.doi.org/10.1097/00007691-200412000-00016
79. Jones MJ, Fejes AP, Kobor MS. DNA methylation,
genotype and gene expression: who is driving and who
is along for the ride? Genome Biol 2013; 14:126;
PMID:23899167; http://dx.doi.org/10.1186/gb-2013-
14-7-126
80. Simpson KL, Weaver KJ, de Villers-Sidani E, Lu JY,
Cai Z, Pang Y, Rodriguez-Porcel F, Paul IA, Merzenich
M, Lin RC. Perinatal antidepressant exposure alters
cortical network function in rodents. Proc Natl Acad
Sci U S A 2011; 108:18465-70; PMID:22025710;
http://dx.doi.org/10.1073/pnas.1109353108
81. Harrington RA, Lee LC, Crum RM, Zimmerman AW,
Hertz-Picciotto I. Prenatal SSRI use and offspring with
autism spectrum disorder or developmental delay. Pedi-
atrics 2014;133:e1241-8; PMID:24733881; http://dx.
doi.org/10.1542/peds.2013-3406
82. Clements CC, Castro VM, Blumenthal SR, Rosenfield
HR, Murphy SN, Fava M, Erb JL, Churchill SE, Kai-
mal AJ, Doyle AE, et al. Prenatal antidepressant expo-
sure is associated with risk for attention-deficit
hyperactivity disorder but not autism spectrum disorder
in a large health system. Mol Psychiatry 2014; in press;
PMID:25155880
83. Hamilton M. A rating scale for depression. J Neurol,
neurosurgeryPsychiatry 1960; 23:56-62.
84. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A
comparison of normalization methods for high density
oligonucleotide array data based on variance and bias.
Bioinformatics (Oxford, England) 2003; 19:185-93.
85. Storey JD, Dai JY, Leek JT. The optimal discovery pro-
cedure for large-scale significance testing, with applica-
tions to comparative microarray experiments.
Biostatistics (Oxford, England) 2007; 8:414-32.
12 Volume 0 Issue 0Epigenetics
